Centre for Medicines Discovery, Nuffield Department of Medicine, NDM Research building, Old Road Campus, Oxford OX3 7FZ, U.K.
Alzheimer's Research UK Oxford Drug Discovery Institute, NDM Research Building, Old Road Campus, Oxford OX3 7FZ, U.K.
J Med Chem. 2024 Nov 14;67(21):18943-18956. doi: 10.1021/acs.jmedchem.4c01320. Epub 2024 Oct 19.
The S100 protein family functions as protein-protein interaction adaptors regulated by Ca binding. Formation of various S100 complexes plays a central role in cell functions, from calcium homeostasis to cell signaling, and is implicated in cell growth, migration, and tumorigenesis. We established a suite of biochemical and cellular assays for small molecule screening based on known S100 protein-protein interactions. From 25 human S100 proteins, we focused our attention on S100A4 because of its well-established role in cancer progression and metastasizes by interacting with nonmuscle myosin II (NMII). We identified several potent and selective inhibitors of this interaction and established the covalent nature of binding, confirmed by mass spectrometry and crystal structures. showed on-target activity in cells and inhibition of cancer cell migration. The identified S100A4 inhibitors can serve as a basis for the discovery of new cancer drugs operating via a novel mode of action.
S100 蛋白家族作为受 Ca 结合调节的蛋白-蛋白相互作用衔接蛋白发挥功能。各种 S100 复合物的形成在细胞功能中发挥核心作用,从钙稳态到细胞信号转导,并与细胞生长、迁移和肿瘤发生有关。我们建立了一套基于已知 S100 蛋白-蛋白相互作用的小分子筛选的生化和细胞测定法。在 25 种人类 S100 蛋白中,我们专注于 S100A4,因为它通过与非肌肉肌球蛋白 II(NMII)相互作用在癌症进展和转移中具有明确的作用。我们鉴定了几种该相互作用的有效且选择性抑制剂,并通过质谱和晶体结构证实了结合的共价性质。 在细胞中显示出针对靶标的活性,并抑制癌细胞迁移。鉴定出的 S100A4 抑制剂可以作为发现通过新型作用模式起作用的新型癌症药物的基础。